Second‐line lurbinectedin as a new treatment option for small‐cell lung cancer: Preliminary results in real‐clinical practice

INTRODUCTION: Few strategies exist for treatment of patients with small‐cell lung cancer (SCLC) extended‐stage after failure of first‐line platinum‐based chemotherapy. Lurbinectedin is a novel RNA‐polymerase‐II inhibitor investigated as a second‐line therapy for SCLC. However, its efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Toublanc, Anne‐Claire, Guecamburu, Marina, Veillon, Rémi, Rosellini, Pietro, Girodet, Pierre‐Olivier, Zysman, Maeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346176/
https://www.ncbi.nlm.nih.gov/pubmed/35715960
http://dx.doi.org/10.1111/1759-7714.14464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346176/
https://www.ncbi.nlm.nih.gov/pubmed/35715960
http://dx.doi.org/10.1111/1759-7714.14464

Ejemplares similares